Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$63.56 USD

63.56
1,078,273

-1.70 (-2.60%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $63.34 -0.22 (-0.35%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $65.26, representing a +0.66% change from its previous close.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress

While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales

Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.

CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $55.89, indicating a +1.49% shift from the previous trading day.

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.91, moving +0.34% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.02, representing a -0.05% change from its previous close.

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $57.96, marking a -1.29% move from the previous day.

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

Charles River (CRL) Forges Collaboration With Ship of Theseus

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.19, marking a +1.72% move from the previous day.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $65.06, signifying a +0.71% move from its prior day's close.

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates

bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.